title: Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy.
abstract: BACKGROUND
  Complementary therapies are frequently used by patients with inflammatory bowel disease (IBD). The aim of this study was to evaluate the efficacy and safety of long-term therapy with a new Boswellia serrata extract (Boswelan, PS0201Bo) in maintaining remission in patients with Crohn's disease (CD).
  
  
  METHODS
  In 22 German centers a double-blind, placebo-controlled, randomized, parallel study was performed. In all, 108 outpatients with CD in clinical remission were included. Patients were randomized to Boswelan (3×2 capsules/day; 400 mg each) or placebo for 52 weeks. The primary endpoint was the proportion of patients in whom remission was maintained throughout the 52 weeks. Secondary endpoints were time to relapse, changes of Crohn's Disease Activity Index (CDAI), and IBD Questionnaire (IBDQ) scores.
  
  
  RESULTS
  The trial was prematurely terminated due to insufficient discrimination of drug and placebo with regard to the primary efficacy endpoint. A total of 82 patients were randomized to Boswelan (n=42) or placebo (n=40). Sixty-six patients could be analyzed for efficacy. 59.9% of the actively treated patients and 55.3% of the placebo group stayed in remission (P=0.85). The mean time to diagnosis of relapse was 171 days for the active group and 185 days for the placebo group (P=0.69). With respect to CDAI, IBDQ, and laboratory measurements of inflammation, no advantages in favor of active treatment were detected. Regarding safety concerns, no disadvantages of taking the drug compared to placebo were observed.
  
  
  CONCLUSIONS
  The trial confirmed good tolerability of a new Boswellia serrata extract, Boswelan, in long-term treatment of CD. However, superiority versus placebo in maintenance therapy of remission could not be demonstrated.
authors.affiliation: Department of Gastroenterology, Diabetes and Internal Medicine, Hospital Porz am Rhein, Cologne, Germany. W.Holtmeier@khporz.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Holtmeier
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Jan
authors.initials: J
authors.lastname: Preiss
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kruis
authors.forename: Stephan
authors.initials: S
authors.lastname: Böhm
authors.forename: Christian
authors.initials: C
authors.lastname: Maaser
authors.forename: Andreas
authors.initials: A
authors.lastname: Raedler
authors.forename: Carsten
authors.initials: C
authors.lastname: Schmidt
authors.forename: Jörg
authors.initials: J
authors.lastname: Schnitker
authors.forename: Joachim
authors.initials: J
authors.lastname: Schwarz
authors.forename: Martin
authors.initials: M
authors.lastname: Zeitz
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Caspary
mesh_terms: D000328:Adult; D000368:Aged; D029743:Boswellia / Q000737:chemistry*; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010936:Plant Extracts